Last reviewed · How we verify
SBI-100 Ophthalmic Emulsion, 1.0%
SBI-100 Ophthalmic Emulsion, 1.0% is a Small molecule drug developed by Skye Bioscience, Inc.. It is currently in Phase 2 development.
At a glance
| Generic name | SBI-100 Ophthalmic Emulsion, 1.0% |
|---|---|
| Sponsor | Skye Bioscience, Inc. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SBI-100 Ophthalmic Emulsion, 1.0% CI brief — competitive landscape report
- SBI-100 Ophthalmic Emulsion, 1.0% updates RSS · CI watch RSS
- Skye Bioscience, Inc. portfolio CI
Frequently asked questions about SBI-100 Ophthalmic Emulsion, 1.0%
What is SBI-100 Ophthalmic Emulsion, 1.0%?
SBI-100 Ophthalmic Emulsion, 1.0% is a Small molecule drug developed by Skye Bioscience, Inc..
Who makes SBI-100 Ophthalmic Emulsion, 1.0%?
SBI-100 Ophthalmic Emulsion, 1.0% is developed by Skye Bioscience, Inc. (see full Skye Bioscience, Inc. pipeline at /company/skye-bioscience-inc).
What development phase is SBI-100 Ophthalmic Emulsion, 1.0% in?
SBI-100 Ophthalmic Emulsion, 1.0% is in Phase 2.